X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with SUVEN LIFE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs SUVEN LIFE - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH SUVEN LIFE PANACEA BIOTECH/
SUVEN LIFE
 
P/E (TTM) x 171.2 19.2 894.0% View Chart
P/BV x 3.8 3.6 107.0% View Chart
Dividend Yield % 0.0 1.1 -  

Financials

 PANACEA BIOTECH   SUVEN LIFE
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
SUVEN LIFE
Mar-16
PANACEA BIOTECH/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs149339 43.9%   
Low Rs82144 57.0%   
Sales per share (Unadj.) Rs84.139.2 214.4%  
Earnings per share (Unadj.) Rs-18.37.5 -245.4%  
Cash flow per share (Unadj.) Rs-6.78.8 -76.3%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs83.749.0 170.8%  
Shares outstanding (eoy) m61.25127.28 48.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.46.2 22.3%   
Avg P/E ratio x-6.332.4 -19.5%  
P/CF ratio (eoy) x-17.227.5 -62.7%  
Price / Book Value ratio x1.44.9 28.0%  
Dividend payout %026.8 0.0%   
Avg Mkt Cap Rs m7,07430,732 23.0%   
No. of employees `0002.81.0 288.3%   
Total wages/salary Rs m1,449416 348.0%   
Avg. sales/employee Rs Th1,874.15,236.1 35.8%   
Avg. wages/employee Rs Th527.0436.5 120.7%   
Avg. net profit/employee Rs Th-407.7995.5 -41.0%   
INCOME DATA
Net Sales Rs m5,1544,995 103.2%  
Other income Rs m100194 51.6%   
Total revenues Rs m5,2545,189 101.2%   
Gross profit Rs m-7661,233 -62.2%  
Depreciation Rs m711167 425.2%   
Interest Rs m1,50354 2,773.1%   
Profit before tax Rs m-2,8811,205 -239.1%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m17255 6.6%   
Profit after tax Rs m-1,121950 -118.1%  
Gross profit margin %-14.924.7 -60.3%  
Effective tax rate %-0.621.2 -2.8%   
Net profit margin %-21.819.0 -114.4%  
BALANCE SHEET DATA
Current assets Rs m3,8104,986 76.4%   
Current liabilities Rs m8,3651,042 802.6%   
Net working cap to sales %-88.479.0 -111.9%  
Current ratio x0.54.8 9.5%  
Inventory Days Days15661 255.3%  
Debtors Days Days6739 171.8%  
Net fixed assets Rs m14,4803,126 463.3%   
Share capital Rs m61127 48.2%   
"Free" reserves Rs m9033,717 24.3%   
Net worth Rs m5,1276,236 82.2%   
Long term debt Rs m5,832432 1,349.0%   
Total assets Rs m19,4338,079 240.5%  
Interest coverage x-0.923.2 -3.9%   
Debt to equity ratio x1.10.1 1,640.8%  
Sales to assets ratio x0.30.6 42.9%   
Return on assets %2.012.4 15.8%  
Return on equity %-21.915.2 -143.6%  
Return on capital %3.618.9 19.3%  
Exports to sales %24.587.5 28.0%   
Imports to sales %10.212.2 83.3%   
Exports (fob) Rs m1,2644,371 28.9%   
Imports (cif) Rs m525611 85.9%   
Fx inflow Rs m1,5394,666 33.0%   
Fx outflow Rs m942942 100.0%   
Net fx Rs m5973,724 16.0%   
CASH FLOW
From Operations Rs m599922 65.0%  
From Investments Rs m-438-619 70.7%  
From Financial Activity Rs m-303-698 43.3%  
Net Cashflow Rs m-141-396 35.7%  

Share Holding

Indian Promoters % 74.5 63.4 117.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 0.0 -  
FIIs % 1.3 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 36.5 64.7%  
Shareholders   10,259 37,287 27.5%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   CADILA HEALTHCARE  TTK HEALTHCARE  MERCK LTD  BIOCON LTD  J.B.CHEMICALS  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 23, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - NOVARTIS COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS